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Abstract
Background: Single cell network profiling (SCNP) utilizing flow cytometry measures alterations in intracellular signaling
responses. Here SCNP was used to characterize Acute Myeloid Leukemia (AML) disease subtypes based on survival, DNA
damage response and apoptosis pathways.
Methodology and Principal Findings: Thirty four diagnostic non-M3 AML samples from patients with known clinical
outcome were treated with a panel of myeloid growth factors and cytokines, as well as with apoptosis-inducing agents.
Analysis of induced Jak/Stat and PI3K pathway responses in blasts from individual patient samples identified subgroups
with distinct signaling profiles that were not seen in the absence of a modulator. In vitro exposure of patient samples to
etoposide, a DNA damaging agent, revealed three distinct ‘‘DNA damage response (DDR)/apoptosis’’ profiles: 1) AML blasts
with a defective DDR and failure to undergo apoptosis; 2) AML blasts with proficient DDR and failure to undergo apoptosis;
3) AML blasts with proficiency in both DDR and apoptosis pathways. Notably, AML samples from clinical responders fell
within the ‘‘DDR/apoptosis’’ proficient profile and, as well, had low PI3K and Jak/Stat signaling responses. In contrast,
samples from clinical non responders had variable signaling profiles often with in vitro apoptotic failure and elevated PI3K
pathway activity. Individual patient samples often harbored multiple, distinct, leukemia-associated cell populations
identifiable by their surface marker expression, functional performance of signaling pathway in the face of cytokine or
growth factor stimulation, as well as their response to apoptosis-inducing agents.
Conclusions and Significance: Characterizing and tracking changes in intracellular pathway profiles in cell subpopulations
both at baseline and under therapeutic pressure will likely have important clinical applications, potentially informing the
selection of beneficial targeted agents, used either alone or in combination with chemotherapy.
Citation: Rosen DB, Putta S, Covey T, Huang Y-W, Nolan GP, et al. (2010) Distinct Patterns of DNA Damage Response and Apoptosis Correlate with Jak/Stat and
PI3Kinase Response Profiles in Human Acute Myelogenous Leukemia. PLoS ONE 5(8): e12405. doi:10.1371/journal.pone.0012405
Editor: Robert E. Means, Yale Medical School, United States of America
Received May 13, 2010; Accepted July 26, 2010; Published August 25, 2010
Copyright:  2010 Rosen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Nodality Inc. funded this research. Nodality had a role in study design, data collection and analysis, decision to publish and preparation of the
manuscript.
Competing Interests: G.P.N. is a consultant, Chairman of the Scientific Advisory Board, and holder of equity in Nodality, Inc. Although Nodality Inc. funded this
research, this does not alter the authors’ adherence to the PLoS ONE policies on sharing data and materials.
* E-mail: wjfantl@stanford.edu
Introduction
Proteomic technologies that can monitor aberrant cell signaling
in disease hold promise in enabling more accurate diagnosis and
prognosis, as well as predicting response to therapeutic agents
[1–3]. Single cell network profiling (SCNP) utilizing flow
cytometry differs from most proteomic technologies by measuring
modulated phospho-protein and other signaling protein responses
at the single cell level [3–4]. Several studies have shown that in
hematological malignancies, induced protein phosphorylation was
more informative than its frequently measured basal phosphory-
lation state, revealing signaling deregulation consequent to the
numerous molecular changes characteristic of transformed cells
[5–8]. Profiling at the single cell level allows deregulated pathways
to be identified in rare cell populations which would otherwise be
missed by alternative technologies. Acute Myeloid Leukemia
(AML) is characterized by uncontrolled proliferation of myeloid
progenitors in the bone marrow [9–10]. An accretion of genetic
alterations in these cells arrests their normal differentiation and
results in a clinically heterogeneous disease challenging successful
treatment [11–15]. The net result of these molecular changes is
alteration of proteins within signal transduction networks that
drive functional changes in cell proliferation, survival, differenti-
ation, progression and cellular responses to drug therapy [16–21].
Supporting this, a prior study classified AML disease via a series
of in vitro functional performance tests in response to a panel of
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applied to AML samples [5]. In that study, a limited set of AML
cellular response profiles were revealed, most notably potentiated
p-Stat3/p-Stat5 signaling post stimulation with G-CSF, which was
associated with a negative outcome for patients receiving standard
AML chemotherapy. These data corroborate many studies
describing a strong tie between the Jak/Stat signaling pathway
with tumorigenesis, especially in myeloid malignancies such as
juvenile myelomonocytic leukemia and myeloproliferative neo-
plasms [22–25]. The involvement of Jak/Stat signaling in
tumorigenesis is plausible, since phosphorylation and dimerization
of Stat proteins results in their translocation to the nucleus where
they activate a variety of transcriptional programs, including gene
sets involved in cell cycle progression and survival [22–23,26–27].
In the AML study by Irish, although a subset of samples were
identified in which potentiated p-Stat3/p-Stat5 signaling correlat-
ed with clinical refractoriness to chemotherapy, not all AML
patients who were refractory to chemotherapy showed a
potentiated p-Stat3/p-Stat5 signaling response, suggesting the
role of alternate oncogenic pathways in their leukemia [5]. In a
recent report, SCNP analysis of a separate cohort of AML samples
taken at diagnosis was used to describe correlations between an
expanded panel of intracellular signaling pathways with clinical
response to induction therapy [28].
In this report, we describe a detailed biological characterization
of the same AML samples (used in the clinical study) based on the
activities of their intracellular signaling pathways and their
relationships to each other. In addition to Jak/Stat signaling,
other pathways were included to provide a more expansive view of
aberrant myeloid biology in AML including alternative pathways
by which cells evade apoptosis ([29], Figure 1). Analysis of Jak/
Stat, PI3K, DNA damage response (DDR) and apoptosis pathway
activities characterized biologically distinct patient-specific pro-
files, even within cytogenetically and cell surface uniform patient
subgroups. Thus, while AML is known to be clinically heteroge-
neous, the biology described in this study shows that it is reducible
to a limited number of intracellular signaling pathways highlight-
ing survival pathways, DDR and their link to apoptosis.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Ethics Review Board of the University Health Network, University
of Toronto hospital. All patients provided written informed
consent for the collection of samples and subsequent analysis.
Patient Samples
Thirty four diagnostic cryopreserved non-M3 AML peripheral
blood mononuclear cell (PBMC) samples taken from patients
within the University Health Network, University of Toronto were
used in this study. Patient characteristics are shown in Table S1.
All patients had given their consent for the collection and use of
samples for institutional review board (IRB) approved research
purposes. All clinical data were de-identified in compliance with
Health Insurance Portability and Accountability Act (HIPPA)
regulations. Induction chemotherapy consisted of at least one cycle
of cytarabine-based standard induction therapy (daunorubicin
60 mg/m
2 63 days, cytarabine 100–200 mg/m
2 continuous
infusion 67 days) [30] and responses were measured after one
cycle of induction therapy. The criteria for reporting an outcome
as complete response (CR) were defined as follows: marrow
aspirate with less than 5% leukemic blasts, neutrophils greater
than 1,000/mcL, platelets greater than 100,000/mcL and no
residual evidence of extramedullary disease. Leukemic samples
Figure 1. Signaling, DDR and apoptosis pathways evaluated in AML blasts. Jak/Stat & PI3K growth and survival pathways were measured in
response to modulation with cytokines, interleukins, growth factors and chemokines in AML samples. DDR and apoptotic machinery were measured
after in vitro exposure of AML samples to etoposide and staurosporine.
doi:10.1371/journal.pone.0012405.g001
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considered non-complete response (NR). Patient outcomes were
blinded until completion of experiment and acquisition of data.
Cell Preparation
Samples were thawed at 37uC and resuspended in RPMI 1640
1% FBS. Amine aqua (Invitrogen) was used to determine cell
viability according to the manufacturer’s protocol. Cells were
resuspended in RPMI 1% FBS, divided into aliquots of 100,000
cells/condition and rested for 2 hours at 37uC. For apoptosis
assays, cells were incubated with staurosporine or etoposide for
6 hours and 24 hours respectively. These time points were chosen
based on data generated from foundational experiments in AML
cell lines and myeloid cells gated from healthy PBMCs, such that
only some, but not all cells underwent apoptosis. For all other
assays, cells were incubated at 37uC with modulators as described
in Tables S2A and S3 for 3–15 minutes. Since the amount of
sample was limiting the decision was taken to measure signaling in
response to multiple modulators, rather than multiple time points
with fewer modulators. The latter is planned for future studies.
Cells were subsequently fixed with paraformaldehyde and
permeabilized with 100% ice-cold methanol as previously
described [31–33]. For apoptosis assays, cells were re-stained with
amine aqua before fixation and permeabilization. Cell lines U937
and GDM-1 as well as PBMC and BMMC samples from healthy
donors were included as controls to ensure quality of assay
performance.
Flow cytometry determinations of survival, proliferation,
DDR and apoptotic pathways
Methanol permeabilized cells were washed with PBS 0.5% BSA
0.05% NaN3 (FACS Buffer), pelleted, and incubated with
antibodies to cell surface antigens CD33 and CD45 [31–33].
The latter allowed leukemic blasts to be delineated and
distinguished from non-myeloid cells. Concurrently with surface
marker antibodies cells were incubated with antibodies recogniz-
ing intracellular signaling molecules within survival, proliferation,
DDR or apoptosis pathways (Tables S2 and S3). Antibodies were
used at saturating concentrations, pre-determined from titrations
in cell lines or in the myeloid cell population of cryopreserved
PBMCs from healthy donors. Antibody specificity was determined
by use of isotype controls or, in the case of phospho-antibodies,
pre-blocking with the phospho-peptide epitope against which the
antibodies were generated (data not shown).
Data Acquisition and Cytometry Analysis
Data was acquired using FACS DIVA software (BD) on an LSR
II Flow Cytometer (BD) equipped with a high throughput sampler
(HTS) and gated using FlowJo (Treestar). For all analyses, dead
cells and debris were excluded by forward scatter (FSC), side
scatter (SSC) and amine aqua viability dye. Leukemic cells were
identified as cells that lacked the characteristics of mature
lymphocytes (CD45
++ CD33
2), and that fit the CD45 and
CD33 vs. right angle light scatter characteristics consistent with
myeloid leukemia cells [33], Figure S1).
Metrics
Several metrics were developed to measure the level of
activation of an intracellular signaling protein (See Methods &
Figure S2). The ‘‘Basal’’ metric quantifies the level of activation for
a protein in its resting state. The ‘‘fold’’ metric is the level of
activation of a signaling molecule after treatment with a modulator
compared to its level of activation its basal state. The ‘‘Total’’
metric measures the total magnitude of an activated protein and
includes the level of basal and induced protein activation. It is
more relevant for pathway measurements regulated by activity
thresholds. For apoptosis assays, the percentage of cells that
undergo cell death in response to an agent was measured with the
amine aqua viability dye and with antibodies against cleaved
PARP [28].
The following metrics were applied to all nodes, (See Figure S2):
Basal: log2 [Median fluorescence intensity (MFI)(Unmodu-
lated)/MFI(Autofluorescence)]
Fold: log2 [MFI(Modulated)/MFI(Unmodulated)]
Total: log2 [MFI(Modulated)/MFI(Autofluorescence)]
Apoptosis was calculated as the percentage of induced c-PARP
+
and/or Aqua
+ cells:
% Apoptotic = % c-PARP
+ and/or Aqua
+.
Apoptosis: % Apoptotic (Modulated) - % Apoptotic (Un-
modulated) (See Figure S2).
Samples displaying high basal apoptosis (greater than 60%) after
overnight incubation in media were excluded from the apoptosis
analyses. Analysis of p-Chk2 induction was performed in non-
apoptotic c-PARP
2 cells.
Principle Component analysis (PCA)
PCA was performed as described [34] for Jak/Stat and PI3K
nodes using both ‘‘Fold and ‘‘Total’’ metrics of induced pathway
activity along with the corresponding basal nodes.
Choice of Node/Metrics for PCA
All node/metrics were independently tested by univariate
analysis for their ability to classify patients based on their disease
response to standard induction therapy. Jak/Stat and PI3K nodes
that stratified clinical CR and NR patients (area under the curve of
the receiver operator characteristic (AUCROC) .0.6 and p,.05)
are listed in Table S4 and were used for principle component
analyses and for selecting examples of the node/metrics that were
used to construct the heat-maps.
SCNP Assay Terminology
The term ‘‘signaling node’’ is used to refer to a proteomic
readout in the presence or absence of a modulator. For example,
the response to G-CSF stimulation can be measured using p-Stat5
as readout. That signaling node is designated ‘‘G-CSFRp-Stat5’’.
Several metrics (normalized assay readouts summarized below and
defined in Figure S2) are applied to interpret the biology of each
signaling node and are noted following the node e.g. ‘‘G-CSFRp-
Stat5 | Fold’’, ‘‘G-CSFRp-Stat5 | Total’’ or ‘‘p-Stat5 | Basal’’.
Results
Given the prosurvival role of Jak/Stat and PI3K signaling in
cancer, functional performance testing via SCNP analysis of these
pathways was carried out in AML blasts after their exposure to a
panel of modulators known to play a role in myeloid biology
through engaging these pathways [24–25,35–38].
Jak/Stat pathway activity
To assess the activity and inducibility of the Jak/Stat pathway,
samples were treated with G-CSF, IL-6, IL-27, IL-10, IFNa and
IFNc, known to activate the Jak/Stat pathway. AML samples
were characterized by the magnitude of their basal Jak/Stat
pathway activity as well as by the induced responses (Fold metric)
and total level of Jak/Stat pathway activation (Total metric) with
examples shown by the heat-maps in Figure 2A). In many, but not
all cases, the latter two metrics used paralleled each other. Low or
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proteins were associated with gated AML blasts from CR patients
exemplified by the 2D flow plots shown for responses of sample
UHN_0713 to G-CSF and IL-27 (Figure 2B). In contrast,
potentiated Jak/Stat signaling was observed as well as increased
pathway activity in cells taken from patients whose leukemia was
non-responsive to induction chemotherapy, as exemplified in a 2D
flow plot for myeloid-gated cells for sample UHN_9172
(Figure 2B). In most NR patient samples Jak/Stat signaling was
elevated in a cell subpopulation in response to multiple cytokines
(right hand side of heat-map in Figure 2A), whereas cells of most
CR patients were largely non-responsive (grouped towards the left
hand side of the heat-map in Figure 2A). IL-27 and IL-6-
mediated-phosphorylation of Stat3 were closely correlated, as
would be expected for two cytokines sharing the gp130 common
signal transduction receptor subunit [39–41].
PI3K pathway activity
A second major survival pathway interrogated in this study was
PI3K, known to play a role in most cancers [24–25,42].
Converging signals from the PI3K/mTor and Ras/Erk pathways
result in phosphorylation of ribosomal protein S6 which correlates
with increased protein translation of mRNA transcripts that
encode proliferation and survival promoting proteins [43–44].
Analogously to activation of the Jak/Stat pathway, application
of known activators of the PI3K pathway including FLT3L, SCF
and SDF-1a broadly grouped AML samples by the magnitude of
their signal transduction responses (Fold metric) and overall
pathway activity (Total metric) represented by measurements of p-
Akt and p-S6 (Figure 2C). In the same manner that low levels of
modulated Jak/Stat responses and Jak/Stat pathway activity were
seen in leukemic cells from CR patients (Figure 2A), samples in
which p-Akt/p-S6 signaling was low or absent (exemplified by the
2D flow plot for sample UHN_8362 in Figure 2D) were also
associated with clinical responsiveness to chemotherapy. Addi-
tionally, in the same manner that high levels of induced Jak/Stat
responses and high levels of Jak/Stat pathway activity were seen in
leukemic cells from NR patients, elevated PI3K pathway responses
were also associated with clinical non-response to chemotherapy
(exemplified by the 2D flow plot for sample UHN_4353 in
Figure 2D). Importantly, no associations could be made between
cytogenetic risk category and the French American British
category (FAB) [18] within these signaling responses (Figure 2A
and 2C).
Correlated measures of induced JAK/STAT and PI3K
signaling reveals AML blasts with distinct pathway
responses
In order to understand the activation state for both the Jak/Stat
and PI3K pathway activities in individual AML samples, principal
component analyses were performed for each pathway in its basal
state as well as its functionally potentiated state combining
readouts from multiple modulators known to activate each
pathway [34]. Induced pathway activity, rather than basal
pathway activity, could more readily reveal distinct patient-specific
functional response patterns (Figure 3). The data revealed that
Figure 3. Pathway analysis of induced Jak/Stat and PI3K activity reveals distinct profiles. Principal Component Analysis (PCA) of NR
samples (unfilled red squares) compared to CR samples (filled blue circles) for Jak/Stat and PI3K signaling. The metrics used in the analysis were
‘‘basal’’, ‘‘fold’’ and ‘‘total’’. (A) Basal signaling: basal metric values for p-Stat1, p-Stat3, p-Stat5 and p-Stat6 were chosen to represent Jak/Stat pathway
signaling, while the basal values for p-Erk, p-S6 and p-Akt were chosen to represent the PI3K pathway. The first principal component for the Jak/Stat
pathway explained 85% of the variance while the one for the PI3K pathway explained 71% of the variance. (B) Induced signaling: the metrics used in
the analysis were ‘‘fold’’ and ‘‘total’’ metric for the same intra-cellular readouts used for the PCA of basal signaling. The percentage of variance
explained by the first principal component for induced Jak/Stat signaling was 66% and for induced PI3K signaling it was 46%. The PCA reveals a
heterogeneity of profiles for NR samples when treated with modulators which is not seen in the PCA of untreated samples in their basal state.
doi:10.1371/journal.pone.0012405.g003
Figure 2. Induced Jak/Stat and PI3K/S6 signaling varies among AML samples. Pathway activity is represented by heat-maps. Blue: Low
Signaling, Red: High Signaling, scaled for an individual readout/metric. (A) Jak/Stat pathway activity was measured after treatment of AML samples
with IL-27, IL-6, and G-CSF. Heat map of Jak/Stat signaling responses, where each row represents a specific readout and metric such as: p-Stat1 | Basal,
IL-27 R p-Stat1 | Total. The samples have been ordered according to IL-27 R p-Stat3 | Total, since this node had the highest AUC and p-value for
stratifying CRs from NRs [28]. Cytogenetic risk and FAB categories are noted for each sample. (B) Exemplary 2D flow plots showing signaling
responses to G-CSF or IL-27 treatment. (C) PI3K pathway activity was measured after treatment of AML samples with FLT3L, SCF and SDF-1a. Heat
map of PI3K signaling responses, where each row represents a specific readout and metric. Patient samples have been ordered according to FLT3L R
p-Akt | Fold responses. (D) Exemplary 2D Flow plots showing signaling responses to FLT3L or SCF treatment.
doi:10.1371/journal.pone.0012405.g002
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such that activity was high or low for both pathways or high for
one and low for the other pathway (Figure 3B). Interestingly,
although there are only 9 samples from CR patients (Figure 3,
filled blue circles), a low signaling capacity in both the Jak/Stat
and PI3K/S6 pathways was associated with clinical response to
chemotherapy. By contrast, augmented signaling responses from
one or both the Jak/Stat and PI3K pathways were observed in
most samples from chemotherapy refractory patients (Figure 3,
unfilled red squares). Furthermore, in a sub-group of NR AML
blast samples (Figure 3, red squares in the lower left hand
quadrant) low level signaling responses in both Jak/Stat and PI3K
pathways were seen, suggesting that other pathways could be
contributing to clinical refractoriness to chemotherapy. Taken
together, these data suggest that activation of the PI3K and Jak/
Stat pathways (or pathways or cell states which are more
proximally causal, but correlated with the activities seen via
PI3K and Jak/Stat), might oppose response to chemotherapy.
Measurements of DDR and apoptosis with in vitro
exposure to etoposide and staurosporine
In addition to the major role played by survival pathways in
AML, the DDR pathway is also critical, as DNA damaging agents
are at the core of most AML treatment regimens [30]. Many
agents used to treat AML promote double stranded DNA breaks
resulting in activation of cell cycle checkpoints which suspend
passage through the cell cycle and allow time for DNA repair
[45–48]. If the resultant damage cannot be repaired then cells are
triggered to undergo apoptosis. In this study, DDR and apoptosis
were measured simultaneously in AML blasts, post exposure to
etoposide, using antibodies against phospho-threonine 68 on the
checkpoint kinase, Chk2, and against cleaved PARP respectively.
Etoposide, is a topoisomerase ll inhibitor, that induces DNA
double-stranded breaks [45,49]. Three distinct responses exem-
plified by the 2D flow plots in Figure 4A were observed: (1) AML
blasts with a defective DDR and failure to undergo apoptosis (2)
AML blasts with proficient DDR and failure to undergo apoptosis
(3) AML blasts with proficiency in both DDR and apoptosis
(Figure 4A). Notably, all CR samples were exemplified by the third
profile whereas NR samples were exemplified by all three response
profiles.
To determine whether the apoptotic machinery was intact in
etoposide profiles 1) and 2), cells were exposed to staurosporine, a
multi-kinase inhibitor that promotes apoptosis through G1 arrest
without the participation of DDR as described for etoposide [50].
Apoptosis was measured using fluorochrome-conjugated antibod-
ies against cleaved caspase 3 and cleaved PARP in addition to a
cell viability dye. The data shown are with cleaved PARP and the
cell viability dye. Cleaved caspase 3 closely mirrored the cleaved
PARP data but in the interests of brevity are not shown. Apoptosis
responses were evaluable in 26/33 of the AML samples (See
Methods) and are depicted by the scatter plot in Figure 4B.
A comparison of etoposide versus staurosporine-mediated
apoptosis showed different response profiles for each sample at
the timepoint chosen for the assay (Figure 4B). Many samples in
which the majority of the leukemic blasts were refractory to
etoposide were responsive to staurosporine. This implies that the
apoptotic machinery per se was intact in these cells and that the
resultant refractory response to etoposide could be the result of
ineffective communication between the machinery of the DDR
with that of apoptosis (exemplified by sample UHN_0401,
Figure 4C). Other categories of response shown are relative
refractoriness to both agents (exemplified by sample UHN_8190,
Figure 4C) or responsiveness to both agents (exemplified by sample
UHN_8303, Figure 4C). Furthermore, the plot shows percentage
of cells within an AML sample undergoing apoptosis and for no
sample was this value 100% at the timepoints chosen in this study
(Figure 4B). This indicates that within an AML sample there are
blast cell subsets with different sensitivities to each agent.
In spite of the small and biased (for clinical response) sample set,
all samples with blast subsets refractory to in vitro etoposide
exposure, regardless of their staurosporine response, were derived
from the NR patient sample subgroup (Figure 4B). Apoptosis
responses identified all CR patients as apoptosis competent to both
agents. However, a negative apoptotic response could not predict
all NR patients, underscoring the fact that in vitro responses alone
to apoptosis stimulating agents are only part of the equation that
describes a clinical outcome (Figure 4B).
Associations Between in vitro apoptosis profiles with Jak/
Stat and PI3K pathway activity
To relate proliferation and survival signaling to in vitro apoptotic
potential, the Jak/Stat and PI3K pathway activities observed in
leukemic samples (Figures 2 and 3) were analyzed in the context of
the in vitro apoptotic responses described above (Figure 4B).
Overall, Jak/Stat signaling responses were of variable magnitude
for samples with relatively low or high responsiveness to etoposide
(Figure 5A, 5B, 5C). This was also true for samples that were
sensitive to staurosporine (Figure 5A, 5B, samples UHN_5643,
UHN_0521, UHN_5684 and 5C). However, for four samples with
the lowest relative response (relative refractoriness) to staurospor-
ine, Jak/Stat pathway responses were augmented (Figure 5A, 5B,
samples UHN_4353, UHN_9172, UHN_8314 and 5C). Pearson
and Spearman coefficients showed that there was in general a
statistically significant negative correlation between staurosporine
induced apoptosis and Jak/Stat signaling in this AML sample set,
with outliers clearly apparent (Figure 5D). Statistical significance
was found for the Jak/Stat PCA value with even greater statistical
significance observed for individual nodes such as IL-6 or IL-27
induced Stat signaling (Figure 5D). Pearson and Spearman
coefficients revealed a lack of correlation for Jak/Stat signaling
with etoposide response (Figure 5D).
Consistent with their roles in survival there was an inverse
correlation between levels of growth factor (SCF and FLT3L) and
chemokine (SDF-1a)-mediated-p-Akt and p-S6 signaling and in
vitro apoptotic response. This relationship was statistically signif-
icant as shown by computing the Pearson and Spearman
correlation coefficients (Figure 5G, 5H). Thus, induced PI3K
pathway signaling tended to be lower for samples that were
apoptosis proficient to both etoposide and staurosporine
(Figure 5E, 5F, samples UHN_5684, UHN_8825 and
UHN_8451 and 5G). Greater induced p-Akt and p-S6 levels
were observed in samples refractory to staurosporine and/or
etoposide (Figure 5E, 5F, samples UHN_0341, UHN_5643 and
UHN_4353, 5G).
When taken together, trends for apoptosis, Jak/Stat and PI3K
pathway activities (Figures 3, 4, and 5) and clinical outcomes
(Table S1) suggest that there are limited number of pathway
profiles associated with CR patients, whereas in NR patients many
different pathway mechanisms may have evolved for the leukemia
to be refractory to chemotherapy. Notably, all samples from CR
patients had blast cell subsets that were sensitive to in vitro
staurosporine and etoposide-mediated apoptosis and in general
had low Jak/Stat and PI3K pathway responses (Figure 3B,
5C, 5G). Most clinical NR samples that were competent to
undergo in vitro apoptosis had an absent or low PI3K response
(Figure 3B, 5G), suggesting that other pathways could be
contributing to clinical refractoriness to chemotherapy. All other
Pathway Profiles in AML
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staurosporine exposure with different degrees of elevated Jak/Stat
and/or PI3K pathway activation.
Leukemic samples with two blast populations that each
harbor cell subpopulations with distinct pathway profiles
Analysis of CD33 and CD45 surface expression of all samples
within this AML cohort defined three patient samples with two
distinguishable leukemic cell subpopulations, referred to as Blast 1
and Blast 2. In all cases, Blast 1 was defined as a cell subset with
higher CD33 and CD45 levels, whereas Blast 2 cells had lower
levels of these surface proteins. Given the distinct signaling profiles
identified for cell subsets within samples harboring only one
myeloid blast population as defined by CD33 and CD45
expression, in the preceding data of this study, it seemed likely
that samples harboring two myeloid blast populations could
harbor distinct signaling profiles. Although seemingly homoge-
neous by surface phenotype, SCNP revealed distinguishable
signaling responses within individual cells in each blast population
measured simultaneously. In what follows, signaling and apoptosis
data from two of the three samples, both from NR patients, are
shown in Figure 6. Blast populations 1 and 2 from sample
UHN_0577 were refractory to etoposide-mediated apoptosis
although both populations exhibited DDR, albeit to different
magnitudes as seen by the frequencies of blasts with increased
phosphorylation of p-Chk2 (Figure 6A, Table S5). Exposure of the
samples to staurosporine revealed that the apoptotic machinery
was intact in both blast populations suggesting that etoposide
refractoriness was the result of disabled communication between
DDR and the apoptotic machinery. Comparison of each blast
subset for its response to G-CSF revealed minimal increases in p-
Stat3 and p-Stat5. However, inspection of the PI3K pathway
revealed that Blast 1, but not Blast 2 had two discernible blast cell
subsets with different levels of p-Akt and p-S6 in the basal state.
Blast 2 had only one ‘‘low’’ level p-Akt and p-S6 blast cell subset.
Furthermore, in Blast 1, FLT3L was able to induce both p-Akt and
p-S6 signaling in the ‘‘low level’’ basal population. In contrast, for
Blast 2 the predominant response to FLT3L was an increase in p-
S6 alone. Using the metric of ‘‘total’’ as a measure of overall
pathway activity (Table S5), there was greater overall pathway
activity for Blast 1 than for Blast 2 in both the basal and FLT3L-
potentiated states reflecting significant contributions of both basal
and evoked signaling responses.
The two blast populations in sample UHN_8093 were both
refractory to etoposide possibly through different mechanisms
since there was a greater p-Chk2 response in Blast 1 and a much
reduced DDR in Blast 2 (Figure 6B). Blast 1 was very responsive to
staurosporine which indicated that the apoptotic machinery is
intact and that the etoposide refractoriness in Blast 1 could be
accounted for by failure of DDR to communicate with the
apoptotic machinery. In contrast, Blast 2 was refractory to
staurosporine-mediated apoptosis. Notably, in Blast 2 G-CSF
mediated greater increases in phosphorylated Stat3 and Stat5
compared to the increases seen in Blast 1. This was reflected by
both the ‘‘fold’’ and ‘‘total’’ metrics (Figure 6B, Table S5).
Inspection of PI3K pathway activity revealed that only a small
blast cell subset responded to FLT3L treatment with the majority
of cells remaining unresponsive. These data suggest that the higher
activity seen for the Jak/Stat pathway for Blast 2 may account for
its refractoriness to in vitro apoptosis and non-response in the clinic
consistent with the data in Figure 5.
Discussion
The current study was designed to determine whether
individual AML samples can be characterized based on in vitro
functional performance tests using SCNP to measure survival
pathways, DDR and in vitro apoptosis. The major findings were
that: (i) an individual sample can be comprised of leukemic blast
subsets with distinct Jak/Stat, PI3K, DDR and apoptosis pathway
responses, (ii) exposure of samples to modulators allowed these
pathway responses to be revealed, (iii) PI3K pathway activity was
high in most samples that were refractory to apoptosis-inducing
agents in vitro, (iv) Jak/Stat pathway activity was high in samples
refractory to staurosporine but only in some samples refractory to
etoposide, (v) in vitro DDR and apoptosis profiles were variable in
leukemic blasts between different samples and also within the same
sample and (vi) SCNP of the pathways chosen reveal a restricted
number of profiles for AML blasts from CR patients and multiple
profiles for AML blasts from NR patients.
Thus, responders to chemotherapy demonstrated little variation
in the signaling potential of the pathways evaluated (that is, cells
remained relatively unperturbed by environmental stimuli ap-
plied). As such, in the CR samples both the potentiated responses
to myeloid activators of the Jak/Stat and PI3K pathways, as well
as ‘‘basal’’ pathway activity tended to be low (Figure 3) whereas
DDR with subsequent apoptosis was robust after in vitro etoposide
exposure (Figure 4A). By contrast, robust Jak/Stat and PI3K
responses were revealed in most NR samples (Figure 3). These
data are consistent with, and expand upon previous findings
linking functional alterations in Jak/Stat signal transduction with
poor response to chemotherapy in AML patients [5]. In addition,
all samples with impaired DDR or proficient DDR without
subsequent apoptosis were NRs (Figure 4A). A subset of NR
samples were competent to undergo in vitro apoptosis and had low
PI3K and Jak/Stat pathway responses suggesting that in these
samples alternative pathways could be contributing to clinical
refractoriness to chemotherapy (Figure 3). The data suggest that
while DDR, Jak/Stat, and PI3K pathways might serve as useful
indicators of the biological underpinnings of therapeutic responses,
additional inquiry into alternative pathways might be required to
more fully complete the characterization of response.
This study used 34 diagnostic PBMC samples taken from
patients for which clinical outcomes were blinded. However, the
sample set was unintentionally biased with samples predominantly
from NR, female patients of younger age with intermediate
cytogenetics (Table S1). In spite of these limitations, univariate
analysis of this sample set and an independent sample set (with 57
CR samples out of a total of 88 samples) from a separate institution
revealed common nodes for CR and NR stratification suggesting
that survival, DDR and apoptosis pathways may be relevant ways
to characterize AML disease subtypes with further follow-up
warranted in additional AML sample cohorts [28].
The proliferative and survival properties of the Jak/Stat and
PI3K pathways most likely play a central role in AML
leukemogenesis as well as in refractoriness and resistance to
Figure 4. Distinct in vitro DDR and apoptosis response profiles identified in AML samples. DDR and apoptosis were measured by p-Chk2
and Aqua positivity with cleaved PARP respectively. (A) Three DDR/apoptosis profiles identified in AML samples after 24h in vitro exposure to
etoposide. (B) Scatter plots to show correlations between apoptosis response of AML samples to etoposide and staurosporine. (C) Exemplary
histograms showing cleaved PARP readouts for different responses to etoposide and staurosporine.
doi:10.1371/journal.pone.0012405.g004
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transcription factors are known to play a critical role in normal
and leukemic hematopoiesis targeting transcription of genes
involved in proliferation, survival and differentiation [51–54].
Receptors that signal through Stat3 and Stat5 are present on AML
blasts where they can be activated by a wide variety of growth
factors, interleukins and cytokines [55]. Furthermore, in a recent
study, the level of Stat5 transcriptional activity was shown to
regulate the balance between proliferation and differentiation in
hematopoietic stem cells/progenitor cells by activating specific
genes associated with these processes [56]. The same group
showed that high levels of Stat5 activity disrupted myelopoiesis.
Additionally, although frequently cited as anti-survival, recent
reports have described a wide variety of roles for Stat1 including
cell proliferation, survival, apoptosis, and differentiation [57].
Here, Stat1 is activated in some samples simultaneously with Stat3
and Stat5, although its precise functional role warrants further
investigation. In the current study, CR samples showed low or
absent Jak/Stat responses and a subset of NR samples showed
high magnitudes of Jak/Stat responses while the remaining NRs
displayed a continuum of responses. (Figure 2A, B). These data
suggest that certain levels of Stat activity may be necessary to
generate the appropriate transcriptional program necessary for
maintaining a particular clonal state of an AML blast cell subset.
In addition, deregulation of the PI3K/mTor signaling pathway
has been described in 50–80% of AML cases contributing to the
survival and proliferation of AML blast cells [58–59]. Many causes
for pathway deregulation have been cited such as activating
mutations in FLT3 and Kit receptors, overexpression of the PI3K
class 1A p110d isoform as well as gain of function mutations in N-
and K-Ras [37,60–63]. In this study, PI3K pathway activity was
determined by measuring levels of p-Akt and p-S6 ribosomal
protein as pathway readouts in response to myeloid modulators,
FLT3L, SCF and SDF-1a. Consistent with its role in cancer cell
survival [24], potentiated levels of p-Akt and p-S6 were lower in
CRs and elevated in clinical NRs, although the two clinical
categories were not mutually exclusive since several NR samples
had low potentiated PI3K pathway activity (Figure 2C, D).
Moreover, alternative mechanisms of refractoriness could arise
from increased DDR, failure to undergo DDR and/or inoperative
communication between DDR and apoptosis [46–47]. For a
response to a DNA damaging agent, DNA lesions recruit multi-
protein DNA damage sensor complexes that associate with DNA
damage transducer proteins such as ataxia telangectasia mutated
(ATM), a kinase which upon activation phosphorylates Thr68
(T68) of the checkpoint kinase Chk2. The resultant delay in cell
cycle progression provides cells with a chance to repair the DNA
damage. If repair fails, cells undergo apoptosis [46–48]. In this
study three DDR/apoptosis profiles distinguished AML samples.
In the first, minimal p-Chk2 response was observed and
consequently no apoptotic response. In the second profile, there
seemed to be a failure for DDR to translate into apoptosis and in
the third, DDR, apoptosis and their communication was intact.
Notably, all clinical responsive patients fell into this latter category.
Further sample cohorts are needed to see whether this association
between in vitro apoptotic sensitivity and clinical response holds,
potentially providing a valuable means for predicting clinical
outcomes.
The robust activation of two major survival pathways shown in
a subset of AML samples provided a rationale for evaluating
apoptotic proficiency in this sample cohort. In vitro exposure of
samples to etoposide and staurosporine [49–50], two agents that
induce apoptosis by different mechanisms, identified distinct blast
subsets with different responses to each agent between individual
samples and also within the same sample (Figure 4B, 4C, Figure 6).
Samples sensitive to both agents were taken from CR patients.
However, this apoptotic proficiency was also observed in some NR
patient samples. There are several explanations to account for the
unexpected in vitro apoptotic response of NR samples, principally
that the in vitro apoptotic responses were not measured with the
drugs used clinically (ara-C/daunorubicin) by which the NRs were
categorized. Further, although etoposide, ara-C and daunorubicin
all induce DNA damage, they have different mechanisms of action
and are substrates for different transporters [64–66] and thus
might not mimic the in vivo responses. It is also possible that the
AML biology characterized for these samples is not represented by
clinical definitions of NR and CR. Furthermore, in all cases, only a
fraction of cells undergo apoptosis and the phenotype of the non-
responding cells may account for the apparent disconnect between
apoptosis seen in vitro versus the clinical NR.
In order to understand whether there was a link between
signaling by survival pathways and in vitro apoptotic responses,
correlations (Figure 5) were computed from the data depicted in
Figures 3 and 4B. Notably, when evaluated for Jak/Stat and PI3K
pathway activity, most samples refractory in vitro to either or both
etoposide and staurosporine had a cell subset that displayed
potentiated PI3K signaling (Figure 5E –5H). In contrast, samples
refractory to staurosporine displayed elevated Jak/Stat pathway
activity whereas there were variable levels of Jak/Stat pathway
activity across a range of etoposide induced responses (Figure 5A –
5D). Given the fine balance between levels of p-Stat5 that, via a
transcriptional program in vivo, regulate blast cell proliferation
versus disruption of differentiation, the in vitro experimental
conditions utilized here may not have allowed these more subtle
changes to be observed between Stat activity and DDR induced
apoptosis [56]. It is very likely that these two common survival
pathways are playing a major role in conferring refractoriness to
chemotherapy, but that alternative, as yet unrevealed, pathways
also make a contribution.
Several AML samples within this cohort had two blast cell
populations discernible by their surface phenotype suggestive of
cell populations representing different stages of differentiation. Of
the two samples described in this manuscript, SCNP revealed that
each blast cell population had its own distinct signaling and
Figure 5. Correlations between Jak/Stat and PI3K pathway activity with apoptotic responses. Scatter plots were generated to determine
the correlations between pathway activity (PCA analysis of modulated Jak/Stat and PI3K signaling) with apoptosis responses to etoposide and
staurosporine. Filled blue circles denote samples from CR patients and unfilled red squares denote samples from NR patients. (A) Scatter plot to show
correlations between response to etoposide and staurosporine with exemplary 2D flow plots (B) showing Jak/Stat pathway responses after treatment
with a specific modulator. (C) Scatter plots showing correlations between PCA of Jak/Stat pathway activity with either etoposide or staurosporine. (D)
Pearson and Spearman correlation coefficients and probabilities show a general inverse correlation between Jak/Stat pathway activity with apoptotic
responsiveness to staurosporine but not to etoposide with outliers shown in the plot. (E) Scatter plot to show correlations between response to
etoposide and staurosporine with exemplary 2D flow plots (F) showing PI3K pathway responses after treatment with a specific modulator. (G) Scatter
plots showing correlations between PCA of PI3K pathway activity with either etoposide or staurosporine. (H) Pearson and Spearman correlation
coefficients and probabilities show a general inverse correlation between PI3K pathway activity with apoptotic responsiveness to etoposide and
staurosporine with outliers shown in the plot.
doi:10.1371/journal.pone.0012405.g005
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SCNP assays to samples taken over time from the same patient it
may be possible to determine which blast population confers
refractoriness to chemotherapy.
Further correlations to defined genetic abnormalities driving
these signaling observations could underscore their potential roles
in driving AML disease; such as analysis of intracellular signaling
pathways in the context of FLT3 mutational status (manuscript in
preparation). The output from such studies could be to guide the
choice of available investigational and approved agents to provide
benefit for those AML patients refractory to current chemotherapy
regimens [21,67–68].
Supporting Information
Figure S1 Sequential gating scheme shown by 2D flow plots A)
Non-cellular debris was excluded using a FSC and SSC gate. B)
Non-viable cells were excluded with a SSC and aqua viability dye
gate. C) Leukemic blasts were gated by CD45, CD33.
Found at: doi:10.1371/journal.pone.0012405.s001 (2.10 MB TIF)
Figure S2 Definition of Metrics A) Summary of metrics used
and the role each has in determining a different measure of
signaling biology. Median Fluorescence Intensities (MFI) were
calculated for leukemic blast cells under each condition and used
to compute the metrics that represented protein expression,
signaling and apoptosis, as described in Materials and Methods.
Apoptosis was measured by levels of c-caspase 3, c-PARP as well
as cells that were positive for the aqua viability dye. Measurements
for cleaved caspase 3 were found to be correlated with cleaved
PARP, but this was not the case for cleaved PARP and aqua.
Therefore apoptosis metrics incorporated measurements for aqua
and cleaved PARP to quantify cells that became positive for c-
PARP alone or for both aqua and c-PARP.
Found at: doi:10.1371/journal.pone.0012405.s002 (3.13 MB TIF)
Table S1 Patient demographics and clinical characteristics. All
25 NRs represent primary refractory AML. The ‘‘other’’ values for
race are black and Hispanic subgroups. *Poor prognosis samples
have one or more high risk features: age $60 years, unfavorable
cytogenetics, FLT3-ITD positive or secondary AML. Criteria for
sample inclusion in this study: diagnostic prior to initiation of
chemotherapy, AML classification by French American British
(FAB) criteria as M0 through M7 (and excluding M3) and data for
clinical response to induction therapy.
Found at: doi:10.1371/journal.pone.0012405.s003 (0.07 MB
PDF)
Table S2 Antibodies and reagents used in study.
Found at: doi:10.1371/journal.pone.0012405.s004 (0.25 MB
PDF)
Table S3 Fluorochrome conjugated antibodies used to measure
intracellular pathway activity.
Found at: doi:10.1371/journal.pone.0012405.s005 (0.05 MB
PDF)
Table S4 Jak/Stat and PI3K pathway nodes that stratified
patient response to chemotherapy (NRs versus CRs). Criteria for
nodes to stratify patient responses: p-Value ,0.1, AUC .0.6.
Filters for induced signaling: Fold metric = Log2 Mean Fold
Signaling .0.25, Total metric = when the Pearson correlation
between basal and induced signal is ,0.75.
Found at: doi:10.1371/journal.pone.0012405.s006 (0.08 MB
PDF)
Table S5 Quantification of pathways in blast 1 and blast 2
populations from samples depicted in Figures 6A and 6B.
Found at: doi:10.1371/journal.pone.0012405.s007 (0.08 MB
PDF)
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